Compare Becton Dickinson and Co (BDX) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs General Motors Company — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while General Motors Company trades at $76.69 (market cap $69.31B). The key difference: General Motors Company is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | GM | |
|---|---|---|
Market Cap | $41.51B | $69.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $86.38 |
52-Week Low | $135.49 | $48.89 |
Enterprise Value | $57.97B | $172.65B |
Dividend Yield | 2.79% | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
General Motors (GM) trades at $76.72, down 1.45% on the day, with a bearish technical signal from moving averages. The company shows strong cash flow from operations at $26.87B for 2025 and has beaten earnings estimates for three consecutive quarters. Recent news highlights GM's strategic pivot into energy and domestic manufacturing expansion, supported by a 63% analyst buy rating. Valuation metrics include a P/E of 28 and P/S of 0.4, indicating potential value relative to sales.
GM's outlook is mixed: solid cash generation and analyst optimism (consensus target $102) contrast with declining net margins (1.38% in 2025) and rising debt-to-asset ratios (46.79% in 2024). Risks include competitive pressures and macroeconomic headwinds, but the stock offers upside if margin improvements and energy initiatives materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
